{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444453889
| IUPAC_name = 1-(4-chlorophenyl)-5-methoxypentan-1-one ''O''-2-aminoethyl oxime
| image = Clovoxamine.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 54739-21-8
| ATC_prefix = none
| PubChem = 6335903
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2105603
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7I22J7RY2A
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4891461

<!--Chemical data-->
| C=14 | H=21 | Cl=1 | N=2 | O=2
| molecular_weight = 284.78 g/mol
| smiles = COCCCCC(=NOCCN)C1=CC=C(C=C1)Cl
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C14H21ClN2O2/c1-18-10-3-2-4-14(17-19-11-9-16)12-5-7-13(15)8-6-12/h5-8H,2-4,9-11,16H2,1H3/b17-14+
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = XXPVSQRPGBUFKM-SAPNQHFASA-N
}}

'''Clovoxamine''' ([[International Nonproprietary Name|INN]]) (developmental code name '''DU-23811''') is a [[drug]] that was discovered in the 1970s and was subsequently investigated as an [[antidepressant]] and [[anxiolytic]] agent but was never marketed.<ref name="pmid7046368">{{Cite journal
| pmid = 7046368
| year = 1982
| author1 = Freeman | first2 = J. S. | first3 = A. | first4 = G.
| title = Initial clinical evaluation of a new nontricyclic antidepressant: clovoxamine
| volume = 32
| pages = 69–75
| journal = Advances in Biochemical Psychopharmacology
| last2 = Wakelin
| last3 = Calanca
| last4 = Hole
}}</ref><ref name="pmid2691573">{{Cite journal
| pmid = 2691573
| year = 1989
| author1 = Jesinger | first2 = N.
| title = Anxiety neurosis in general practice. A double-blind comparative study of diazepam and clovoxamine, a novel inhibitor of noradrenaline and serotonin reuptake
| volume = 4
| issue = 4
| pages = 301–311
| journal = International clinical psychopharmacology
| last2 = Gostick
| doi = 10.1097/00004850-198910000-00005
}}</ref><ref name="pmid6872422">{{Cite journal
| doi = 10.1038/clpt.1983.164
| pmid = 6872422
| year = 1983
| author1 = Hurst | first2 = D. R. | first3 = J. H. | first4 = C. H.
| title = Clovoxamine kinetics in an early clinical trial
| volume = 34
| issue = 2
| pages = 266–271
| journal = Clinical pharmacology and therapeutics
| last2 = Jones
| last3 = Wright
| last4 = Jarboe
}}</ref> It acts as a [[serotonin-norepinephrine reuptake inhibitor]] (SNRI), with little affinity for the [[muscarinic acetylcholine receptor|muscarinic acetylcholine]], [[histamine receptor|histamine]], [[adrenergic receptor|adrenergic]], and [[5-HT receptor|serotonin]] [[receptor (biochemistry)|receptor]]s.<ref name="pmid6777458">{{Cite journal
| pmid = 6777458
| year = 1980
| author1 = Saletu | first2 = J. | first3 = P. | first4 = M.
| title = Clovoxamine and fluvoxamine-2 biogenic amine re-uptake inhibiting antidepressants: quantitative EEG, psychometric and pharmacokinetic studies in man
| volume = 49
| issue = 1–2
| pages = 63–86
| journal = Journal of neural transmission
| doi = 10.1007/BF01249190
| last2 = Grünberger
| last3 = Rajna
| last4 = Karobath
}}</ref><ref name="pmid2820327">{{Cite journal
| pmid = 2820327
| year = 1987
| author1 = Bradford | first2 = M. T. | first3 = J.
| title = Biochemical effects in rats after acute and long-term treatment with clovoxamine
| volume = 287
| issue = 2
| pages = 188–202
| journal = Archives Internationales de Pharmacodynamie et de Thérapie
| last2 = Tulp
| last3 = Schipper
}}</ref> The compound is [[chemical structure|structurally]] related to [[fluvoxamine]].

==References==
{{Reflist|2}}

{{Adrenergics}}
{{Serotonergics}}

[[Category:Amines]]
[[Category:Antidepressants]]
[[Category:Chloroarenes]]
[[Category:Ethers]]
[[Category:Oximes]]
[[Category:Serotonin-norepinephrine reuptake inhibitors]]


{{nervous-system-drug-stub}}